Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Pi App Studio launches new features for 2026: payment integration and more convenient app creation options

Pi App Studio launches new features for 2026: payment integration and more convenient app creation options

Odaily星球日报Odaily星球日报2026/01/24 02:50
Show original

According to Odaily, Pi Network announced that Pi App Studio has launched three major updates: simplified Pi payment integration, ad-supported free app creation, and a creator campaign to solicit community feedback. Highlights of the updates include that pioneers can integrate the Test-Pi payment feature without programming by mentioning "Pi payment" in the new app prompt; when the balance is below 0.25 Pi, users can deploy apps by watching ads; and the first 1,000 participants in the feedback survey will receive 5 Pi credits dedicated to App Studio.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11